These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 27267053)

  • 1. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
    Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
    Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
    Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
    Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
    Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
    Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
    JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
    J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
    Janczewska E; Zarębska-Michaluk D; Berak H; Piekarska A; Gietka A; Dybowska D; Mazur W; Belica-Wdowik T; Dobracki W; Tudrujek-Zdunek M; Deroń Z; Buczyńska I; Sitko M; Czauż-Andrzejuk A; Lorenc B; Białkowska-Warzecha J; Citko J; Laurans Ł; Jaroszewicz J; Socha Ł; Tronina O; Adamek B; Horban A; Halota W; Baka-Ćwierz B; Tomasiewicz K; Simon K; Garlicki A; Wawrzynowicz-Syczewska M; Flisiak R
    BMC Infect Dis; 2018 Nov; 18(1):580. PubMed ID: 30445916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
    Değertekin B; Demir M; Akarca US; Kani HT; Üçbilek E; Yıldırım E; Güzelbulut F; Balkan A; Vatansever S; Danış N; Demircan M; Soylu A; Yaras S; Kartal A; Kefeli A; Gündüz F; Yalçın K; Erarslan E; Aladağ M; Harputluoğlu M; Özakyol A; Temel T; Akarsu M; Sümer H; Akın M; Albayrak B; Sen İ; Alkım H; Uyanıkoğlu A; Irak K; Öztaşkın S; Uğurlu ÇB; Güneş Ş; Gürel S; Nuriyev K; İnci İ; Kaçar S; Dinçer D; Doğanay L; Göktürk HS; Mert A; Coşar AM; Dursun H; Atalay R; Akbulut S; Balkan Y; Koklu H; Şimşek H; Özdoğan O; Çoban M
    Turk J Gastroenterol; 2020 Dec; 31(12):883-893. PubMed ID: 33626001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
    Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Pockros PJ; Reddy KR; Mantry PS; Cohen E; Bennett M; Sulkowski MS; Bernstein DE; Cohen DE; Shulman NS; Wang D; Khatri A; Abunimeh M; Podsadecki T; Lawitz E
    Gastroenterology; 2016 Jun; 150(7):1590-1598. PubMed ID: 26976799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
    J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
    Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
    J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
    Shafran SD; Shaw D; Charafeddine M; Agarwal K; Foster GR; Abunimeh M; Pilot-Matias T; Pothacamury RK; Fu B; Cohen E; Cohen DE; Gane E
    J Viral Hepat; 2018 Feb; 25(2):118-125. PubMed ID: 28833938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.